HOME > Investors > Press Releases
2015-12-04
ViroMed and bluebird bio Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
2015-09-01
US FDA Approves VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer by US FDA
2015-03-06
A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
2014-05-16
Disclosure of Clinical Trial Entry & Exit (Voluntary Disclosure)
2014-04-08
Interpretation of ACC.14 Abstract
1 2 3 4 5 6 7 8 9 10